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A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibro-
sis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS-790052), a potent orally
administered nonstructural 5A replication complex inhibitor, in combination with peginterferon a (PEG-IFNa) and ribavirin in
an LT recipient. A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplanta-
tion with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/
mL, and a total bilirubin level of 8.4 mg/dL. Despite partial virological suppression with PEG-IFNa and ribavirin, progressive
allograft failure ensued and culminated in retransplantation at 9 months. Three months after the second transplant, DCV
(20 mg/day), PEG-IFNa2a (180 lg/week), and ribavirin (800 mg/day) were prescribed for early recurrent cholestatic HCV.
Serum HCV RNA became undetectable at week 3 of treatment and remained undetectable during 24 weeks of triple ther-
apy and during the posttreatment follow-up. DCV was well tolerated, and the trough drug levels were within the targeted
range throughout the treatment. The cyclosporine trough levels were also stable during and after therapy. In conclusion, the
lack of anticipated drug-drug interactions between DCV and calcineurin inhibitors and the potent antiviral efficacy of DCV
make this agent (in combination with PEG-IFN and ribavirin) an attractive antiviral regimen worthy of further study in LT
recipients with recurrent HCV. Liver Transpl 18:1053-1059, 2012. VC 2012 AASLD.
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Liver failure and hepatocellular carcinoma due to
chronic hepatitis C virus (HCV) infections are the
leading indications for liver transplantation (LT) in the
United States.1 However, the recurrence of HCV infec-
tions after LT is nearly universal and is characterized
by high serum HCV RNA levels and allograft hepatitis
of variable severity.2,3 The rate of fibrosis progression
is greatly accelerated in these patients versus non-
transplant HCV patients, with 10% to 30% developing
cirrhosis within 5 years of transplantation.4,5 The
accelerated course of recurrent HCV infections is at-
tributable in part to the use of potent immunosup-
pressants, the treatment of acute rejection, and other
donor and recipient factors. Not surprisingly, LT
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recipients with chronic HCV have a significantly lower
5-year survival rate in comparison with other recipi-
ents because of the higher rate of graft failure due to
recurrent disease.6,7
Peginterferon (PEG-IFN)/ribavirin combination ther-
apy is frequently used for select LT recipients with
recurrent HCV infections.8-10 In addition, several
studies have shown that LT recipients who achieve a
sustained virological response (SVR) have significantly
improved survival in comparison with partial respond-
ers as well as untreated patients.11-13 However, many
LT recipients are incapable of starting interferon ther-
apy because of pancytopenia, renal insufficiency,
and/or other medical and psychiatric comorbidities.
In addition, antiviral response rates are lower in LT
recipients versus nontransplant patients (SVR rates of
30% and 45% for patients with genotype 1), in part
because of the use of immunosuppressive agents and
the need for more frequent antiviral medication dose
reductions and/or early discontinuation.8-10 There-
fore, better tolerated and more effective treatments for
LT recipients with recurrent HCV are urgently needed.
The direct-acting antiviral agents telaprevir and boce-
previr, in combination with PEG-IFN and ribavirin,
were recently shown to significantly improve SVR
rates in both treatment-naive patients and previously
treated patients with genotype 1.14-17 However, both
of these agents are contraindicated in LT recipients
because of potentially severe and life-threatening
drug-drug interactions with cyclosporine and tacroli-
mus as well as the lack of efficacy and safety data in
this patient population.18,19 Daclatasvir (DCV), which
is also known as BMS-790052, is an investigational
oral nonstructural 5A replication complex inhibitor in
development with demonstrated antiviral efficacy
when it is combined with PEG-IFN and ribavirin in
treatment-naive patients and previously treated
patients with HCV genotypes 1 and 4.20-25 In phase 2
clinical trials, DCV has generally been well tolerated
in combination therapy, with no unique adverse
events identified to date. Furthermore, in vitro and in
vivo testing suggests that DCV should not lead to any
clinically significant drug-drug interactions when it is
coadministered with other drugs that are metabolized
by cytochrome P450 3A4 (eg, cyclosporine, tacroli-
mus, and sirolimus).24 The aim of this article is to
report the first successful use of a direct-acting antivi-
ral agent (DCV) in combination with PEG-IFN and rib-
avirin in an LT recipient with a severe, interferon-re-
fractory cholestatic HCV infection.
PATIENTS AND METHODS
Antiviral Treatment Regimen
An investigator-initiated, emergency investigational
new drug application (#109,999) was approved by the
US Food and Drug Administration to provide antiviral
treatment for this patient with a severe recurrent cho-
lestatic HCV infection after LT. The treatment protocol
included DCV (Bristol-Myers Squibb, Princeton, NJ;
20 mg/day), PEG-IFNa2a (Genentech, Nutley, NJ; 180
lg/week), and ribavirin (400 mg twice daily) for 24
weeks. A reduced dose of DCV (20 mg) was selected
because of the potential for a theoretically mild drug-
drug interaction with cyclosporine. DCV and cyclospo-
rine are substrates and inhibitors of cytochrome P450
3A4 and P-glycoprotein, respectively; therefore, it was
anticipated that the exposure to DCV might be
increased when it was concomitantly administered
with cyclosporine. The patient was seen at weeks 0, 1,
2, 3, 4, 8, 12, 16, 20, and 24 and at follow-up weeks
12 and 24 at the University of Michigan Institute for
Clinical and Health Research (Ann Arbor, MI). HCV
RNA levels were tested with the Roche Cobas TaqMan
test (lower limit of detection ¼ 43 IU/mL) at weeks 0,
1, 2, 3, 4, 8, 12, and 24 and at follow-up weeks 12
and 24. Written informed consent was obtained from
the patient after a review and approval by the local
institutional review board.
DCV Pharmacokinetics
A morning blood sample was obtained at weeks 2, 4,
6, 8, and 12 so that the DCV trough levels could be
assessed with a validated liquid chromatography/tan-
dem mass spectrometry method.21 In addition, semi-
intensive 6-hour pharmacokinetic sampling was per-
formed at treatment week 2 to estimate the overall ex-
posure and to determine the maximum concentration
and the time to the maximum concentration in the
steady state.
RESULTS
Initial Pretransplant and Posttransplant Course
A 49-year-old female health care provider acquired an
HCV genotype 1b infection after an inadvertent needle
stick in 1990. She was initially treated with interferon
monotherapy without clearance and was retreated
with full-dose PEG-IFN and ribavirin for 48 weeks in
2002; HCV RNA was suppressed to undetectable lev-
els, but this was followed by a posttreatment relapse.
The patient also had a history of diabetes mellitus,
hypertension, and a body mass index of 35 kg/m2.
Her interleukin-28B genotype at rs12979860 was CT.
The patient progressed to decompensated cirrhosis
with ascites, gastrointestinal bleeding, and encephal-
opathy and was listed for transplantation with a
Model for End-Stage Liver Disease (MELD) score of
11. After the diagnosis of a 2-cm hepatocellular carci-
noma, she received a MELD upgrade to 22 points.
While she was hospitalized with a MELD score of 32
and was on hemodialysis, she received a cadaveric
liver graft from a donor who was less than 40 years
old with a cold ischemia time of 9 hours. The induc-
tion immunosuppression consisted of basiliximab
(Simulect, Novartis, East Hanover, NJ) on postopera-
tive days 1 and 4 as well as intraoperative steroids.
She was discharged home on postoperative day 22
with stable liver biochemistries and was receiving cy-
closporine, mycophenolate mofetil, and prednisone.
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Four months after the first transplant, her serum
alkaline phosphatase level was 1525 IU/mL, her bili-
rubin level was 8.4 mg/dL, and her HCV RNA level
was 10.8  106 IU/mL. The evaluation for biliary
strictures was negative, and a liver biopsy sample
showed an intense pericentral cholestatic reaction
with lymphocytic inflammation indicative of recurrent
HCV (Fig. 1A). As a result, PEG-IFNa2a (180 lg/week)
and ribavirin (1200 mg/day) were initiated. At week 4
of the antiviral therapy, her bilirubin level increased
to 17.9 mg/dL, and repeat liver biopsy demonstrated
severe cholestatic HCV with perisinusoidal fibrosis.
Although her HCV RNA level had declined to 3.2 
103 IU/mL at treatment week 12, her cholestasis
worsened with an alkaline phosphatase level of 1959
IU/mL and a bilirubin level of 36.8 mg/dL; the antivi-
ral therapy was discontinued because of her worsen-
ing clinical status (Fig. 2).
The patient was subsequently hospitalized with
severe encephalopathy requiring intubation and coa-
gulopathy with an international normalized ratio of
1.9. She underwent retransplantation with a MELD
score of 36 while she was in the intensive care unit.
In this instance, a graft from a 19-year-old cadaveric
donor was used with a cold ischemia time of only 7
hours. The initial immunosuppression consisted of
cyclosporine, mycophenolate mofetil, and steroids.
She was discharged home 4 weeks later on cyclospo-
rine and prednisone and fully recovered. Twelve weeks
after the second transplant, her alkaline phosphatase
level had risen to 673 IU/mL with an alanine amino-
transferase (ALT) level of 88 IU/mL and a total biliru-
bin level of 1.4 mg/dL. A cholangiogram revealed no
evidence of obstruction, and her serum HCV RNA level
was 4.0  106 IU/mL. Because of the diagnostic
uncertainty, a liver biopsy sample was obtained, and
it showed mild periportal and lobular hepatitis with a
lymphocytic infiltrate (Fig. 1B).
DCV in Combination With PEG-IFN and
Ribavirin Treatment
The patient was started on DCV (20 mg/day), PEG-
IFNa2a (180 lg/week), and ribavirin (800 mg/day) 12
weeks after the second transplant because of the sus-
picion of an early recurrent HCV infection with choles-
tatic features. Concomitant medications included cy-
closporine (75 mg twice daily), prednisone (4 mg/day),
pantoprazole (40 mg/day), nifedipine (60 mg/day),
lasix (20 mg/day), ursodeoxycholic acid (600 mg/
day), erythropoietin (20,000 U/week), and atenolol
(25 mg/day) along with insulin and calcium with vita-
min D. Serum HCV RNA became undetectable at week
3 of antiviral therapy, and there were associated
improvements in serum ALT and alkaline phospha-
tase levels (Fig. 2). At week 16 of antiviral therapy, the
patient experienced an episode of herpes zoster reacti-
vation that was successfully treated with valacyclovir
for 4 weeks.
At treatment week 19, her serum ALT and alkaline
phosphatase levels increased to 99 and 517 IU/mL,
respectively. A liver biopsy sample showed immune-
mediated allograft hepatitis with extensive plasma cell
infiltration and hepatic necrosis. At that time, her
anti-nuclear antibody and anti–smooth muscle anti-
body findings were negative, her quantitative immu-
noglobulin levels were normal, and her cyclosporine
trough level was within the therapeutic range at 100
ng/mL. Because this was felt to be immune-mediated
allograft dysfunction due to interferon, the PEG-IFN
dose was reduced to 135 lg/week, and the predni-
sone dose was increased from 2 to 20 mg/day for the
remainder of the treatment course.
Figure 1. (A) Severe cholestatic HCV infection 4 months after
the first transplant. The left side of the slide shows intense
pericentral hepatocyte balloon degeneration. On the right, a
portal tract can be seen with focal periportal cholestatic ductular
proliferation and lymphocytic inflammation indicative of
recurrent cholestatic DCV (hematoxylin and eosin stain,
magnification 200). (B) Recurrent HCV infection 3 months after
the second transplant. On the right side, a central vein can be
seen with normal pericentral hepatocytes and without
ballooning. On the left, a portal tract can be seen with moderate
lymphocytic inflammation that is characteristic of an early
recurrent HCV infection. In the lobular parenchyma between the
portal tract and central vein, there is mild inflammation with
scattered sinusoidal lymphocytes and a single necrotic
hepatocyte near the portal tract; these are typical features of
recurrent HCV infections.
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After 24 weeks of triple antiviral therapy, PEG-IFN/
ribavirin consolidation therapy was administered for
another 4 weeks. After the cessation of the antiviral
medications at week 28, her serum ALT level was 82
IU/mL, her alkaline phosphatase level was 294 IU/
mL, and her total bilirubin level was normal. At post-
treatment weeks 12 and 24, HCV RNA remained unde-
tectable, and she had a serum ALT level of 50 IU/mL,
an alkaline phosphatase level of 220 IU/mL, and a
total bilirubin level of 0.6 mg/dL. At week 32 after
treatment, the patient was feeling well with normal
liver biochemistries and was receiving cyclosporine (75
mg twice daily), prednisone (5 mg/day), and azathio-
prine (100 mg/day); HCV RNA remained undetectable.
Pharmacokinetic Assessment
The plasma concentrations of DCV at treatment week
2 were 137, 102, 112, 218, 451, and 376 ng/mL
before dosing and 0.5, 1.0, 2.0, 4.0, and 6.0 hours af-
ter dosing, respectively. The trough values at weeks 4,
6, 8, 12, and 24 were 129, 160, 270, 161, and 87 ng/
mL, respectively.
DISCUSSION
A recurrent HCV infection after LT can lead to acceler-
ated allograft injury and fibrosis because of the high
levels of HCV replication and the ongoing suppression
of the host immune response to viral antigens.4,5
Patients who receive monoclonal antibody induction
therapy or require treatment for acute rejection with
pulse steroids are at particular risk for severe recur-
rent HCV infections, and so are recipients of older do-
nor allografts.7,26-28 Our patient developed a severe
recurrent cholestatic HCV infection within 4 months
of her initial transplant in the absence of monoclonal
antibody induction therapy and despite the receipt of
a younger donor liver with a short cold ischemia time.
Despite the minimization of her immunosuppression
and the early introduction of PEG-IFN/ribavirin com-
bination therapy, the patient developed progressive
and life-threatening cholestatic graft failure. Liver bi-
opsy samples at months 4 and 5 showed classic fea-
tures of a severe cholestatic HCV infection (Fig.
1A).28,29 This particular recurrent HCV infection vari-
ant tends to occur within the first year of LT and is
characterized by the development of inflammatory
infiltrates, cholestasis, and hepatocyte ballooning,
which can frequently lead to early graft failure and
premature death. Although there have been case
reports of salvage antiviral therapy, most patients die
of infection or progressive allograft failure.27
Although previous data have shown poor outcomes
with retransplantation in patients with severe recur-
rent HCV infections, a second transplant was offered
Figure 2. Liver biochemistries and
HCV RNA levels during antiviral
therapy. Five months after the first
transplant, the patient was started
on PEG-IFNa2a (180 lg/week) and
ribavirin (1200 mg/day). Despite the
partial suppression of HCV RNA, the
serum alkaline phosphatase and
bilirubin levels continued to rise,
and antiviral therapy was
discontinued 12 weeks later. After
retransplantation, the serum
alkaline phosphatase and total
bilirubin levels nearly normalized,
but they began to rise again with the
reemergence of HCV RNA. Four
months after the second transplant,
the patient was started on DCV (20
mg/day), PEG-IFNa2a (180 lg/
week), and ribavirin (800 mg/day).
Within 3 weeks of the initiation of
therapy, HCV RNA became
undetectable, and there were
concomitant improvements in the
serum alkaline phosphatase and
bilirubin levels. After 24 weeks of
triple therapy, the patient received
another 4 weeks of PEG-IFN/
ribavirin consolidation therapy. The
patient remained well with HCV RNA
undetectable at her last follow-up
(32 weeks after the completion of
treatment).
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to this patient because of her young age, excellent
functional status, and good general health.30-32 Fortu-
nately, she had an adequate physiological reserve to
recover and was discharged home within 4 weeks of
retransplantation. However, when the patient began
to manifest early recurrent cholestasis with associated
histological changes 3 months after her second trans-
plant (Fig. 1B), a potent direct-acting antiviral–based
antiviral therapy (DCV) in combination with PEG-IFN
and ribavirin was initiated.
In contrast to her initial post-LT treatment course,
a rapid suppression of HCV RNA at week 3 was
observed with associated improvements in serum ALT
and alkaline phosphatase levels while she was receiv-
ing DCV in combination with PEG-IFN and ribavirin
(Fig. 2). In addition, HCV RNA remained undetectable
throughout the 24-week course of triple antiviral ther-
apy even though she had been previously treated 3
times without success. Furthermore, viral replication
remained suppressed despite an intensification of her
immunosuppressive regimen due to allograft dysfunc-
tion at week 19 and an intentional reduction in the
dose of PEG-IFN. We considered discontinuing all 3
antiviral agents at this point, but we wanted her to
complete the full course of treatment (24 weeks)
because of her previous lack of clearance with PEG-
IFN and ribavirin. A reduced dose of DCV (20 mg) was
used throughout her treatment because of the poten-
tial for cyclosporine to increase the plasma levels of
DCV. The plasma trough levels of DCV at weeks 2, 4,
8, 12, and 24 ranged from 87 to 270 ng/mL and were
similar to the levels reported for nonimmunosup-
pressed HCV patients receiving DCV at 60 mg/day.21
In addition, the observed maximum concentration of
DCV (451 ng/mL) was similar to the values observed
in nontransplant patients receiving a once daily dose
of 30 mg.21 The time to the maximum concentration
for the patient was 4 hours, which was longer than
the mean time to the maximum concentration previ-
ously reported for nontransplant patients under fast-
ing conditions but was within the range observed
when patients received DCV under fed conditions.
Overall, the exposure observed for this subject was
within the therapeutic range of DCV for which safety
and efficacy have been observed; this suggests that
cyclosporine did not have a clinically significant effect
on her DCV exposure.
Antiviral therapy was well tolerated in this LT recip-
ient, who was receiving concomitant cyclosporine,
prednisone, and several other medications. The epi-
sode of herpes zoster at antiviral treatment week 19
was not felt to be related to the DCV study medication
or the PEG-IFN/ribavirin treatment because solid
organ transplant recipients are known to be at
increased risk for zoster reactivation.33-35 In addition,
the zoster infection improved despite continued antivi-
ral therapy. The other adverse event experienced by
this patient, immune-mediated allograft hepatitis, is
being increasingly reported in LT recipients receiving
interferon.8,36,37 Many HCV patients with immune-
mediated hepatitis have detectable serum autoanti-
bodies and develop a plasma cell–rich infiltrate in the
allograft that responds to increased immunosuppres-
sion. Some investigators have speculated that
immune-mediated hepatitis may be due to the rapid
suppression of HCV RNA and may reflect an immune
reconstitution syndrome like that reported for human
immunodeficiency virus patients treated with antire-
troviral therapy.37 In support of this, interferon ther-
apy can promote HCV-specific CD4 and CD8
responses in the liver, but additional prospective
studies of viral kinetics and intrahepatic immune
responses are needed.38 HCV patients with cholesta-
sis and plasma cell hepatitis on their baseline biopsy
samples or with elevated alkaline phosphatase levels
before antiviral therapy may be at particular risk for
this complication.36,37 Other studies have suggested
that virological responders to interferon therapy who
experience improved liver function and metabolism of
calcineurin inhibitors may be at increased risk of
developing rejection during antiviral therapy.39,40
Although our understanding of this clinicopathologi-
cal entity is evolving, many patients improve with a
reduction or discontinuation of interferon therapy or
with an increase in their immunosuppression, but
cases of progressive hepatitis with graft failure and
death have been reported.36 In the current patient, we
were reluctant to stop the antiviral therapy because of
her progressive liver failure with her first transplant
and her rapid response to the 3-drug antiviral treat-
ment. Therefore, the dose of PEG-IFN was reduced,
and the corticosteroid dose was increased to treat the
immune-mediated allograft hepatitis. Fortunately, this
patient was successfully supported through a full 24-
week course of triple antiviral therapy, and her liver
biochemistries further improved during follow-up. In
addition to being highly effective, DCV was not associ-
ated with any clinically significant drug-drug interac-
tions in our patient. In particular, the trough levels of
cyclosporine remained within the target range of 75 to
125 ng/mL during and after treatment.
In summary, we have reported the first successful
use of a direct-acting antiviral agent in combination
with PEG-IFN and ribavirin in an LT recipient with
severe, interferon-refractory cholestatic HCV. Despite
3 previous attempts at antiviral therapy (including a
course of PEG-IFN and ribavirin after the first trans-
plant), the patient developed early cholestatic HCV af-
ter her second transplant. The rapid suppression of
HCV RNA to undetectable levels within 3 weeks of the
initiation of treatment with DCV and PEG-IFN/riba-
virin along with the improved liver biochemistries sug-
gests that effective antiviral therapy can lead to
improved outcomes in these patients. In addition, the
continued suppression of HCV RNA in this patient de-
spite the need to reduce the PEG-IFN dose and
increase the dose of steroids is encouraging with
respect to the potency and efficacy of DCV-based com-
bination antiviral therapy. Furthermore, the fact that
only 24 weeks of triple antiviral therapy was required
to achieve an SVR in this patient is also promising for
other LT recipients with genotype 1, who frequently
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have difficulty tolerating 48 weeks of treatment. How-
ever, the optimal duration of triple antiviral therapy
for LT recipients with HCV genotype 1a versus LT
recipients with HCV genotype 1b requires further
investigation. The favorable safety profile of DCV in
combination with PEG-IFN and ribavirin that was
observed in this patient and other studies (including
the potentially minimal drug-drug interactions with
calcineurin inhibitors) also makes it an attractive
agent to explore in future studies of LT recipients.
Finally, it is hoped that if combination regimens of
potent oral antiviral agents such as DCV and other
direct-acting antiviral classes such as nonstructural 3
protease inhibitors (asunaprevir and TMC-435) and
nonstructural 5B nucleoside polymerase inhibitors
(INX-189 and GSI-7977) with or without ribavirin can
be safely administered to nontransplant patients,
many additional LT recipients with recurrent HCV will
be able to be treated. However, additional prospective
studies will be needed.41,42
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